A study examined the synergistic anticancer potential of the isothiazolonaphthoquinone-based compound 57, an activator of FOXO nuclear–cytoplasmic shuttling, in combination with selinexor (58), an exportin-1 (XPO1) inhibitor, against breast cancer (Figure 3) [98]. Here, XPO1 is linked to breast carcinoma.